share_log

Stocks of the Hour: Tamboran Res, Sayona Mining, BCAL Diagnostics, Nova Eye Medical

Stocks of the Hour: Tamboran Res, Sayona Mining, BCAL Diagnostics, Nova Eye Medical

热门股票:Tamboran Res、Sayona Mining、BCAL 诊断、Nova Eye Medical
sharecafe ·  2023/08/01 21:50

Tamboran Resources (ASX:TBN) has signed four separate non-binding Letters of Intent with Origin, AGL, EnergyAustralia and Shell Energy Australia to potentially purchase gas from Tamboran's low-reservoir Beetaloo Basin gas assets for a period of up to 10 – 15 years. In response, Managing Director and CEO, Joel Riddle, said: "The initial interest from key East Coast gas buyers for the long-term purchase of Tamboran's low-reservoir CO2 Beetaloo Basin gas volumes demonstrates gas' viability and role in the energy transition in Australia." Shares are trading 3.33 per cent higher at 15.5 cents.

Tamboran Resources (ASX: TBN) 已分别与Origin、AGL、EnergyAustralia和澳大利亚壳牌能源公司签署了四份不具约束力的意向书,有可能在长达10至15年的时间内从坦博兰的低储量Beetaloo盆地天然气资产中购买天然气。作为回应,董事经理兼首席执行官乔尔·里德尔表示:“东海岸主要天然气买家最初对长期购买坦博兰低储层二氧化碳Beetaloo盆地天然气量的兴趣表明了天然气的可行性和在澳大利亚能源转型中的作用。”股价上涨3.33%,至15.5美分。

Sayona Mining (ASX:SYA; OTCQB:SYAXF) announced the first commercial shipment of spodumene concentrate from the North American Lithium operation in Québec, Canada. In response, Sayona's Managing Director, Brett Lynch commented: "We are particularly pleased to make this first shipment in less than two years since NAL's acquisition in August 2021, reflecting the team's strong execution capabilities and commitment." Shares are trading 3.23 per cent higher at 16 cents.

Sayona Mining (ASX: SYA; OTCQB: SYAXF) 宣布,加拿大魁北克的北美锂业务首次商业运送锂辉石精矿。作为回应,Sayona董事经理Brett Lynch评论说:“我们特别高兴能够完成自2021年8月NAL被收购以来不到两年来的第一批货物,这反映了该团队强大的执行能力和承诺。”股价上涨3.23%,至16美分。

BCAL Diagnostics (ASX:BDX) has received breakthrough results from their Precion US study. The Precion result enables blood samples to be analysed in many commercial laboratories worldwide fast tracking market access and penetration. In response, Jayne Shaw, Executive Chair of BCAL commented "We will continue to work closely with leading scientists and doctors as our science team further optimises the test to make it more cost-effective when it is launched as a patient friendly blood test for detecting breast cancer". Shares are trading 81.25 per cent higher at 14.5 cents.

BCAL Diagnostics (ASX: BDX) 的美国Precion研究取得了突破性的结果。Precion的结果使全球许多商业实验室能够对血液样本进行分析,从而快速追踪市场准入和渗透率。作为回应,BCAL执行主席Jayne Shaw评论说:“我们将继续与领先的科学家和医生密切合作,因为我们的科学团队进一步优化该测试,使其在作为检测乳腺癌的患者友好型血液测试推出时更具成本效益”。股价上涨81.25%,至14.5美分。

Nova Eye Medical (ASX:EYE) announced that following the US launch of iTrack, total USA sales in the three months to 31 July 2023 were approx. US$2.2 million, up 32% on the prior corresponding period. In response, Managing Director, Tom Spurling, commented: "We will continue to reactivate inactive customer accounts before turning our focus to win new customer accounts in the remainder of the calendar year." Shares are trading 12 per cent higher at 28 cents.

Nova Eye Medical (ASX: EYE) 宣布,在美国推出iTrack之后,截至2023年7月31日的三个月中,美国的总销售额约为220万美元,比上一同期增长32%。作为回应,董事经理汤姆·斯普林评论说:“在本日历年的剩余时间里,我们将继续重新激活不活跃的客户账户,然后将注意力转向赢得新的客户账户。”股价上涨12%,至28美分。

1x1.png?futu_img_keep_extra_domain=1

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发